Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1-Dexamethasone implant (DEX-I) Treatment | Participants treated with dexamethasone implant (DEX-I). | ||
| Group 2 -aVEGF Treatment | Participants treated with anti-Vascular Endothelial Growth Factor (aVEGF). | ||
| Group 3 -aVEGF & DEX-I Treatment | Participants initially treated with aVEGF and then switched to DEX-I at 3-5 months. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants gaining ≥10 Early treatment diabetic retinopathy study (ETDRS) letters Best Corrected Visual Acuity (BCVA) | Best corrected visual acuity | Up to 3 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult Participants with Diabetic Macular Edema
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andrew Shirlaw | Contact | 844-663-3742 | andrew.shirlaw@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided